Patricia Maria Pontes The

Dr. Patricia Maria Pontes The

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Cadernos de Saude Publica
Verified
Journal Article
Open access
PDF file
PAPaulo Sérgio Dourado Arrais
Paulo Sérgio Dourado Arrais
MVMarisa Perdigão de Negreiros Vianna
Marisa Perdigão de Negreiros Vianna
AZAnamaria Vargas Zaccolo
Anamaria Vargas Zaccolo
LMLuzia Izabel Mesquita Moreira
Luzia Izabel Mesquita Moreira
PTPatricia Maria Pontes The
Patricia Maria Pontes The
SMSotero Serrate Mengue
Sotero Serrate Mengue
O objetivo foi estimar a prevalência do uso de adoçantes pela população adulta brasileira e características dos usuários. Análise de dados da Pesquisa Nacional de Acesso, Utilização e Promoção do Uso Racional de Medicamentos (PNAUM, 2014), um inquérito nacional de base populacional. O desfecho de interesse foi o uso autorreferido de adoçantes entre brasileiros com 20 anos ou mais. As variáveis analisadas foram sexo, idade em anos completos, região do Brasil, escolaridade em anos completos e classificação econômica segundo o Critério Classificação Econômica Brasil da Associação Brasileira de Empresas de Pesquisa (ABEP). Os indicadores das condições de saúde foram: relato de doença crônica não transmissíveis (DCNT), número de DCNT e índice de massa corporal (IMC). A prevalência do uso de adoçantes na população adulta brasileira foi de 13,4% (IC95%: 12,5-14,3), sendo maior entre as pessoas do sexo feminino e no grupo com 60 anos ou mais, nas regiões Nordeste e Sudeste, entre pessoas da classe econômica A/B e entre indivíduos obesos. As pessoas com doenças crônicas (em especial diabetes) foram as que mostraram maior prevalência de uso de adoçantes, sendo o uso maior quanto maior o número de comorbidades relatadas. A prevalência de uso de adoçantes foi de 13,4% e mostrou-se associada a características sociodemográficas e de saúde.

Verified
Journal Article
Open access
PDF file
LCLeidivan Sousa da Cunha
Leidivan Sousa da Cunha
IFIsabelle Magalhães Farias
Isabelle Magalhães Farias
BNBeatriz Maria Dias Nogueira
Beatriz Maria Dias Nogueira
CMCaio Bezerra Machado
Caio Bezerra Machado
FPFlávia Melo Cunha de Pinho Pessoa
Flávia Melo Cunha de Pinho Pessoa
Caroline Aquino Moreira-NunesCaroline Aquino Moreira-Nunes
Caroline Aquino Moreira-Nunes
The JAK2V617F mutation is a major molecular factor in Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) and has been increasingly associated with clonal progression to acute myeloid leukemia (AML), resulting in a poorer prognosis and resistance to conventional therapies. This study integrates a comprehensive literature review with bioinformatic approaches to investigate the potential inhibitory activity of Epigallocatechin Gallate (EGCG), a green tea polyphenol widely recognized for its antioxidant and anticancer properties, on the JAK2V617F mutation. Clinical data from case reports demonstrated heterogeneity in disease progression and frequent therapeutic failures. Molecular docking analysis using the Janus Kinase 2 (JAK2) protein structure (PDB ID: 6D2I) identified a high-affinity binding pocket for EGCG near the V617F mutation site. EGCG exhibited strong binding affinity (−9.2 kcal/mol), forming key interactions with residues Lys581, Ile559, and Leu680, suggesting allosteric modulation of the JH2 pseudokinase domain. To validate our docking protocol, redocking of the known inhibitor AT9283 yielded a favorable Root Mean Square Deviation (RMSD) 2.683 Å and binding energy (−8.3 kcal/mol), confirming the reliability of our approach. Notably, EGCG demonstrated superior binding affinity compared to AT9283 and targets a distinct allosteric site, highlighting its unique mechanism of action and potential as a selective allosteric inhibitor. These findings position EGCG as a promising candidate for future preclinical evaluation, offering a novel strategy to overcome therapy resistance in JAK2V617F-driven malignancies.

22 October 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
FPFlávia Melo Cunha de Pinho Pessoa
Flávia Melo Cunha de Pinho Pessoa
IFIsabelle Magalhães Farias
Isabelle Magalhães Farias
BNBeatriz Maria Dias Nogueira
Beatriz Maria Dias Nogueira
CMCaio Bezerra Machado
Caio Bezerra Machado
IBIgor Valentim Barreto
Igor Valentim Barreto
Caroline Aquino Moreira-NunesCaroline Aquino Moreira-Nunes
Caroline Aquino Moreira-Nunes
Acute leukemias are highly aggressive hematologic malignancies that demand intensive chemotherapy regimens. However, drug toxicity remains a major barrier to treatment success and patient survival. In this context, pharmacogenomics offers a promising strategy by identifying single-nucleotide variants (SNVs) that influence drug metabolism, efficacy, and toxicity, ultimately impacting treatment outcomes. This study analyzed data from the ClinPGx/PharmGKB database to identify clinically annotated variants related to chemotherapy response in Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL). A total of 24 variants were curated for AML and 57 for ALL. Among these, nonsynonymous variants were most frequent in ALL (31.6%), while synonymous variants predominated in AML (33.3%). Although traditionally considered neutral, synonymous and intronic variants may influence gene expression through regulatory or splicing mechanisms. The analysis revealed clinically significant variants associated with chemotherapy response, particularly in the ABCB1 gene, observed in 12.5% of AML and 10.5% of ALL cases. Several variants, particularly TPMT, NUDT15, ABCC1, SLC28A3, and RARG, were associated with severe adverse effects such as myelotoxicity, mucositis, cardiotoxicity, and hepatotoxicity. This study reinforces the importance of genetic variants in modulating the therapeutic response and toxicity to chemotherapy drugs in acute leukemias. Analysis of ClinPGx/PharmGKB data emphasizes ABCB1 as a potential resistance marker and supports pre-treatment genotyping of genes like TPMT and NUDT15 to prevent severe toxicities. Future advances should include the expansion of pharmacogenetic studies in underrepresented populations and the clinical validation of new markers in prospective trials, aiming to consolidate precision medicine as a routine part of the therapeutic management of acute leukemias.

31 December 2024 in Revista Brasileira de Plantas Medicinais
Verified
Journal Article
Open access
PDF file
FNFrancisco Cirineu das Chagas Neto
Francisco Cirineu das Chagas Neto
LLLUZIA LEAL
LUZIA LEAL
PTPatricia Maria Pontes The
Patricia Maria Pontes The
Libidibia ferrea (Mart. ex Tul.) L.P. Queiroz, commonly known as "juc", is a plant of the Fabaceae family, widely distributed in northeastern Brazil. In folk medicine, it is used as an antioxidant, antidiabetic and anti-inflammatory. These effects are mainly attributed to its high content of phenolic compounds and flavonoids. Despite its known use in humans, the use of this plant as an antioxidant supplement for animals remains little explored. This study aimed to compare the levels of phenolic compounds and flavonoids in extracts of leaves and pods of L. ferrea, associating them with the potential for scavenging free radicals, as well as quantifying antinutritional factors. The levels of phenols and flavonoids were quantified by spectrophotometric and the scavenging potential was determined through DPPH radical assay. L. ferrea extracts showed antioxidant activity comparable to vitamin E, with leaf extracts at 50 µg/ml and pod extracts at 10 µg/ml, due to their high phenolic and flavonoid content. The recommended safe intake for animals is up to 115 g of leaf extract and 150 g of pod extract per day. These results suggest the potential of juca extracts as an antioxidant supplement in animal feed, which may contribute to improving animal health and the quality of derived products.